Steven A. Hamilton

Cardiology (AHF, MCS and heart transplantation) fanatic. AHA FIT Laennec Award recipient. Editor, HFR. Lawn tennis enthusiast and timepiece collector.

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

Residual congestion—not simply symptom relief—drives outcomes after hospitalization for acute HF. This review introduces the ICON (Integrated Congestion-Oriented Navigation) framework, integrating lung ultrasound, VExUS, and focused echocardiography to phenotype congestion and guide bedside assessment across hospitalization (https://t.co/AB6GDvK9K4). #HREV

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

The p.Val142Ile (Val122Ile) variant is the most common hereditary ATTR amyloidosis mutation in the U.S., disproportionately affecting individuals of African ancestry. This review highlights ongoing challenges in timely diagnosis, genetic screening, access to specialty care, and equitable treatment, while outlining priorities to improve outcomes through earlier identification, multidisciplinary care, and more inclusive clinical trials. A timely and important read (https://t.co/pKxx0o28pf) #HREV @senthil_selv @KMAlexanderMD @NotNoninvasive

[Pasquale Santangeli @Dr_Santangeli]

Invasive Assessment of Right Ventricular Dysfunction Predicts Periprocedural Outcomes in Patients Undergoing Unplanned Ventricular Tachycardia Ablation @CleClinicHVTI @SroubekJ https://t.co/xThwXiE3pE

[CCF Cardiology Fellows @CCFcards]

Today we had the pleasure of welcoming @KiranKhush1 for a fantastic grand rounds discussing the latest advances in non-invasive heart transplant surveillance. Thank you Dr. Khush for a fabulous lecture and for sharing your professional insights and experiences at noon conference!

[Steven A. Hamilton @SA_Hamilton1]

This is going to be an outstanding experience!!! So proud and happy of my alma mater! As a general fellow the procedural volume was amazing. 317 coronary angiogram and PCI cases including IVUS and FFR/iFR (within just 4 months), > 10 pericardiocentesis, > 50 RHC, > 20 endomyocardial biopsies (shoutout to Dr. Svetlichnaya), > 15 IABPs, 8 PFO closures (shoutout out to Dr Romero) etc. This is going to be even better for the interventional fellows. Apply!

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

🚨 Now Recruiting: Inaugural Interventional Cardiology Fellowship Class (July 2027) 🚨

Train where complex heart disease comes to be treated!

🏥 >800 PCIs annually
📈 Left main PCI volume >4× the national average
🫀 Northern California's highest-volume TAVR center 🔬 KPNC's Structural Heart Hub

Join an outstanding group of interventional cardiologists committed to clinical excellence, innovation, and education.

Learn more and apply: https://t.co/mUDuMrSuII

@ankeetbhatt @SA_Hamilton1 @MariaAnsariMD @SalHernandezMD @JamalRanaMD @cardskrish @KPncalCVfellows

Please repost!

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

U-CARS 2026 highlights: refined β-adrenergic signaling enabling more targeted β-blocker strategies, intercellular crosstalk driving remodeling, and HF as a multisystem (cardio-renal-metabolic) syndrome—pointing toward integrated, precision therapy (https://t.co/ew0YUCjjqr). #HREV

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

Highlights from #UCARs2025: LVAD-driven myocardial recovery, CS care, multidisciplinary shock teams, donor selection, and emerging HF therapy.

A global forum translating cutting-edge science into clinical insights for advanced HF (https://t.co/2J5ohqfuLm). #HREV @StavrosDrakos

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

VO₂max remains the benchmark for CPET in HF, but it often misses subtle functional impairment. Submaximal metrics—VAT, VE/VCO₂ slope, OUES, EOV, O₂ pulse, COP, and VO₂ kinetics—provide powerful prognostic insight and individualized care plans (https://t.co/HiG6dZ0ObL). #HREV

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

Since the 2021 ESC and 2022 AHA/ACC/HFSA HF guidelines, expanding therapies including nsMRAs, incretin-based therapies, rapid GDMT optimization in acute HF, renewed evidence for digoxin, and advances in transcatheter valve repair (https://t.co/UlDbC6pN6U). #HREV @SotiriaLiori

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

Congestion is the hallmark of HF—and the leading cause of hospitalization. Yet up to 1 in 3 patients are discharged still fluid overloaded. This #3CT2025 review highlights emerging tools to improve congestion assessment and management (https://t.co/IZ9vXjQh72). @Jolie_Bruno_

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

Arrhythmias remain a major challenge in patients supported with LVADs. This state-of-the-art review highlights the high burden of AAs/VAs, the impact on RV failure, limitations of current therapies, and the need for close HF–EP collaboration (https://t.co/DNNKPOopj1). #HREV

[CCF Cardiology Fellows @CCFcards]

At #AHA25, @CCFcards represented 3 of 5 national finalists for the @American_Heart Laennec FIT Clinician Award, a distinction recognizing the highest level of clinical reasoning and bedside mastery among trainees nationwide.

@JLabin_MD @YashManiar0 @EliseFraserMD

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

💔🩸 HF and CKD often coexist. EMR-based decision support can boost GDMT use, flag CKD early (via eGFR & UACR), and guide timely therapy. Integrating AI/ML into EMRs could enable personalized, proactive care for HF + CKD (https://t.co/3t4StLGxSH). #HREV @nihardesai927 @yaleHFdoc

[JAHA @JAHA_AHA]

Black heart transplant recipients experience worse 3-year outcomes including graft failure, rejection, and renal disease progression. #AHAJournals @SA_Hamilton1 https://t.co/HaK6ILpqAm

[ELSO @ELSOOrg]

Here in 📄 paper & ink 🖋️!! The 5th #ECMO specialists training manual: the new ELSO Blue Book 📘
Available at #ELSO2025, starting tomorrow!
With all ELSO publications:
📕 The Red Book 6th Edition
📘 Post-cardiotomy #ECLS & temporary MCS in adults
📕 ECPR and Resuscitative #ECMO

[Steven A. Hamilton @SA_Hamilton1]

@KiranKhush1, @brian_wayda, and colleagues demonstrate that racial disparities in outcomes after OHT persist in the contemporary era over the long term. Black patients have more adverse post-OHT events, such as rejection, new onset DM + worsening renal function. Biological differences and susceptibility likely also play a role. Thank you for the mentorship @KiranKhush1 @JAHA_AHA @KPncalCVfellows @StanfordDeptMed @juancbatlle @KatAAClark #disparities #biologicaldifferences #clinicalandpolicychange https://t.co/CKPyEd4NKR. See the elegant accompanying editorial by Batlle and Clark https://t.co/jMSmUVtewn.

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

Congrats to @ankeetbhatt for KP VACCINATE LBCT @ESC2025. Largest RCT ever conducted with >3.6 million patients randomized in 1 month. No effect on vaccination rates but proof-of-concept for large-scale embedded RCT within a LHS!

[Massimo Imazio @ImazioMassimo]

A new concept from 2025 ESC guidelines on myocarditis and pericarditis presented: the IMPS (Inflammatory MyoPericardial Syndrome) acronym. A new term to describe the full spectrum of myocardial and pericardial inflammatory diseases and improve the management of patients.

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

HFpEF is marked by elevated LV filling pressures due to diastolic dysfunction. This review explores how intrathoracic volume & pressure—affected by posture, gravity, obesity, & exercise—shape cardiac filling & highlight research gaps (https://t.co/yx1EJZSXFB). @JLHarrington_MD